Cover Image
市場調查報告書

早產兒視網膜症 : 開發平台分析

Retinopathy Of Prematurity - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 255964
出版日期 內容資訊 英文 36 Pages
訂單完成後即時交付
價格
Back to Top
早產兒視網膜症 : 開發平台分析 Retinopathy Of Prematurity - Pipeline Review, H2 2016
出版日期: 2016年09月14日 內容資訊: 英文 36 Pages
簡介

所謂早產兒視網膜症(ROP)是阻礙早產兒視網膜血管發達的疾病。一般雙眼皆有可能出現,是幼兒期失明和長期性視力降低最常見的要素。早產兒視網膜症發病的風險要素有早產和出生體重超低,多胎生產等。

本報告提供全球各國治療早產兒視網膜症用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查,並將結果概述為以下內容。

目錄

簡介

  • 分析範圍

早產兒視網膜症概要

治療藥的開發

  • 早產兒視網膜症用開發中產品:概要
  • 早產兒視網膜症用開發中產品:比較分析

各企業開發中的早產兒視網膜症治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

早產兒視網膜症治療藥:開發中的產品一覽(各企業)

早產兒視網膜症開發治療藥的企業

  • Acucela Inc.
  • Biomar Microbial Technologies
  • EyeGene, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gene Signal International SA
  • Insmed Incorporated

早產兒視網膜症:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • aganirsen
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • EG-Mirotin
  • emixustat hydrochloride
  • IB-09A0133
  • mecasermin rinfabate (recombinant)
  • R-200
  • ranibizumab
  • 早產兒視網膜症用治療藥

早產兒視網膜症治療藥:開發中產品的最新趨勢

早產兒視網膜症相關的產品開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8462IDB

Summary

Global Markets Direct's, 'Retinopathy Of Prematurity - Pipeline Review, H2 2016', provides an overview of the Retinopathy Of Prematurity pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Retinopathy Of Prematurity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinopathy Of Prematurity and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Retinopathy Of Prematurity
  • The report reviews pipeline therapeutics for Retinopathy Of Prematurity by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Retinopathy Of Prematurity therapeutics and enlists all their major and minor projects
  • The report assesses Retinopathy Of Prematurity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Retinopathy Of Prematurity

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Retinopathy Of Prematurity
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Retinopathy Of Prematurity pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Retinopathy Of Prematurity Overview
  • Therapeutics Development
    • Pipeline Products for Retinopathy Of Prematurity - Overview
  • Retinopathy Of Prematurity - Therapeutics under Development by Companies
  • Retinopathy Of Prematurity - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Retinopathy Of Prematurity - Products under Development by Companies
  • Retinopathy Of Prematurity - Companies Involved in Therapeutics Development
    • Biomar Microbial Technologies
    • F. Hoffmann-La Roche Ltd.
  • Retinopathy Of Prematurity - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AP-202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IB-09A0133 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ranibizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Cancer and Diabetic Retinopathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Retinopathy Of Prematurity - Dormant Projects
  • Retinopathy Of Prematurity - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Retinopathy Of Prematurity, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Retinopathy Of Prematurity - Pipeline by Biomar Microbial Technologies, H2 2016
  • Retinopathy Of Prematurity - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Retinopathy Of Prematurity - Dormant Projects, H2 2016
  • Retinopathy Of Prematurity - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Retinopathy Of Prematurity, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top